185 related articles for article (PubMed ID: 34106156)
1. [Hypersensitivity reactions associated with the use of asparaginase in children with acute lymphoblastic leukemia].
Ovalle B P; Azócar M M; Nicklas D C; Villarroel C M; Morales V J
Andes Pediatr; 2021 Apr; 92(2):182-192. PubMed ID: 34106156
[TBL] [Abstract][Full Text] [Related]
2. Anaphylactic reaction to polyethylene-glycol conjugated-asparaginase: premedication and desensitization may not be sufficient.
Sahiner UM; Yavuz ST; Gökce M; Buyuktiryaki B; Altan I; Aytac S; Tuncer M; Tuncer A; Sackesen C
Pediatr Int; 2013 Aug; 55(4):531-3. PubMed ID: 23910807
[TBL] [Abstract][Full Text] [Related]
3. A comparison of hypersensitivity reactions between intravenous and intramuscular applications of native
Odaman Al I; Özdemir N; Zengin Ersoy G; Bayram C; Vupa Çilengiroğlu Ö; Arslantaş E; Paslı Uysalol E; Ayçiçek A
J Oncol Pharm Pract; 2023 Sep; 29(6):1454-1460. PubMed ID: 36942380
[TBL] [Abstract][Full Text] [Related]
4. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia.
Ettinger LJ; Kurtzberg J; Voûte PA; Jürgens H; Halpern SL
Cancer; 1995 Mar; 75(5):1176-81. PubMed ID: 7850718
[TBL] [Abstract][Full Text] [Related]
5. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
Henriksen LT; Harila-Saari A; Ruud E; Abrahamsson J; Pruunsild K; Vaitkeviciene G; Jónsson ÓG; Schmiegelow K; Heyman M; Schrøder H; Albertsen BK;
Pediatr Blood Cancer; 2015 Mar; 62(3):427-33. PubMed ID: 25418987
[TBL] [Abstract][Full Text] [Related]
6. [Allergic complications of L-asparaginase therapy in children with acute lymphoblastic leukaemia].
Konstantinidis N; Kolarović J; Kaćanski N; Vijatov-Djurić G; Konstantinidis G
Srp Arh Celok Lek; 2011; 139(11-12):749-52. PubMed ID: 22338470
[TBL] [Abstract][Full Text] [Related]
7. Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia.
Mesegué M; Alonso-Saladrigues A; Pérez-Jaume S; Comes-Escoda A; Dapena JL; Faura A; Conde N; Català A; Ruiz-Llobet A; Zapico-Muñiz E; Camós M; Rives S
Hematol Oncol; 2021 Dec; 39(5):687-696. PubMed ID: 34397119
[TBL] [Abstract][Full Text] [Related]
8. Lack of benefit from premedication for pegylated asparaginase during pediatric acute lymphoblastic leukemia/lymphoma therapy: A side-by-side comparison.
Menig S; Dinh A; Angus J; Tucker S; Leger KJ; Rushing T; Orgel E
Pediatr Blood Cancer; 2024 Jan; 71(1):e30716. PubMed ID: 37856184
[TBL] [Abstract][Full Text] [Related]
9. Outcomes Following Discontinuation of E. coli l-Asparaginase Upon Severe Allergic Reactions in Children With Acute Lymphoblastic Leukemia.
Yen HJ; Chang WH; Liu HC; Yeh TC; Hung GY; Wu KH; Peng CT; Chang YH; Chang TK; Hsiao CC; Sheen JM; Chao YH; Chang TT; Chiou SS; Lin PC; Wang SC; Lin MT; Ho WL; Chen YC; Liang DC
Pediatr Blood Cancer; 2016 Apr; 63(4):665-70. PubMed ID: 26703788
[TBL] [Abstract][Full Text] [Related]
10. [New possibilities of treatment with PEG-L-asparaginase in patients with acute lymphoblastic leukemia sensitized to l-asparaginase E.coli and erwinase].
Sikorska-Fic B; Makowska K; Rokicka-Milewska R
Wiad Lek; 1998; 51 Suppl 4():233-6. PubMed ID: 10731974
[TBL] [Abstract][Full Text] [Related]
11. Clinical Characteristics of Intravenous PEG-Asparaginase Hypersensitivity Reactions in Patients Undergoing Treatment for Acute Lymphoblastic Leukemia [Formula: see text].
Browne EK; Moore C; Sykes A; Lu Z; Jeha S; Mandrell BN
J Pediatr Oncol Nurs; 2018; 35(2):103-109. PubMed ID: 29161979
[TBL] [Abstract][Full Text] [Related]
12. L-asparaginase activity and anti-L-asparaginase antibody as biomarkers in estimating PEG-asp-related anaphylaxis risk in childhood acute lymphoblastic leukemia patients.
Cui J; Jiang L; Xu B; Bai Y
Allergol Immunopathol (Madr); 2023; 51(3):28-35. PubMed ID: 37169557
[TBL] [Abstract][Full Text] [Related]
13. The Incidence of Hypersensitivity Reactions to Pegylated Asparaginase in Children With Acute Lymphoblastic Leukemia: A City-wide Experience.
Alrazzak M; Beaupin LK; Kinyoun P; Barth M
J Pediatr Hematol Oncol; 2016 Jan; 38(1):e16-20. PubMed ID: 26558809
[TBL] [Abstract][Full Text] [Related]
14. Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group.
Brigitha LJ; Fiocco M; Pieters R; Albertsen BK; Escherich G; Lopez-Lopez E; Mondelaers V; Vora A; Vrooman L; Schmiegelow K; van der Sluis IM;
Eur J Cancer; 2022 Feb; 162():65-75. PubMed ID: 34954438
[TBL] [Abstract][Full Text] [Related]
15. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia.
Soyer OU; Aytac S; Tuncer A; Cetin M; Yetgin S; Sekerel BE
J Allergy Clin Immunol; 2009 Apr; 123(4):895-9. PubMed ID: 19081614
[TBL] [Abstract][Full Text] [Related]
16. Correlation of L-asp Activity, Anti-L-asp Antibody, Asn and Gln With Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL Patients.
Wu J; Chen C; Huang S; Shen S; Chen J; Zhang S
Technol Cancer Res Treat; 2020; 19():1533033820980113. PubMed ID: 33287663
[TBL] [Abstract][Full Text] [Related]
17. Asparaginase treatment in infants with acute lymphoblastic leukemia; pharmacokinetics and asparaginase hypersensitivity in Interfant-06.
Albertsen BK; Harila-Saari A; Jahnukainen K; Lähteenmäki P; Riikonen P; Möttönen M; Lausen B
Leuk Lymphoma; 2019 Jun; 60(6):1469-1475. PubMed ID: 30632847
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological and clinical monitoring in children with acute lymphoblastic leukemia treated with a biogeneric PEG-l-asparaginase product.
Matteo C; Colombini A; Bettini LR; Porcu L; Barzaghi S; Ceruti T; Silvestri D; Amoroso A; Dell'Acqua F; Gotti G; Nastasi C; Zucchetti M; Rizzari C
Pediatr Blood Cancer; 2022 Sep; 69(9):e29753. PubMed ID: 35561075
[TBL] [Abstract][Full Text] [Related]
19. Comparison of hypersensitivity reactions to PEG-asparaginase in children after intravenous and intramuscular administration.
August KJ; Miller WP; Dalton A; Shinnick S
J Pediatr Hematol Oncol; 2013 Oct; 35(7):e283-6. PubMed ID: 23619117
[TBL] [Abstract][Full Text] [Related]
20. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
